Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Diethylcarbamazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | MAPT | P10636 | 2/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylcarbamazine SCHEMBL37736 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL4740035 | 0.87 | KDM4E (0.81) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL2719699 | 0.83 | HTR1A (0.92) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL67289 | 0.80 | HTR1A (1.00) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL1819685 | 0.80 | HTR1A (1.00) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL10412471 | 0.78 | HTR1A (0.96) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL2319899 | 0.77 | HTR1A (0.79) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Stearic Acid SCHEMBL10523823 | 0.76 | HTR1A (0.66) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| SCHEMBL11096507 | 0.75 | HTR1A (0.89) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Citric Acid SCHEMBL11188422 | 0.75 | ALDH1A1 (0.62) | KDM4EALDH1A1LMNAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | disclosed |
| WO-2022172225-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-08-18 | — | — | WO | disclosed |
| WO-2011145105-A2 | HERBAL COMPOSITION FOR TREATMENT OF FILARIASIS | DAS PREMANANDA (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-7192608-B2 | Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-03-20 | — | — | US | disclosed |
| EP-1238662-B1 | Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules | DAINIPPON SUMITOMO PHARMA CO (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | disclosed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | disclosed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20030039699-A1 | Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1238662-A2 | Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-4889709-A | OIL, FOAMING AGENT, PROPELLANT AND SOLID PARTICLES INCLUDING MAGNESIUM ALUMINUM SILICATE | PRODUCT RESOURCES INTERNATIONAL, INC. (US) | 1989-12-26 | — | — | US | disclosed |